Berkeley Lights, Inc.
5858 Horton Street
Suite 320
Emeryville
California
94608
United States
38 articles with Berkeley Lights, Inc.
-
Berkeley Lights Reports Financial Results for Second Quarter of Fiscal Year 2020
8/25/2020
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended June 30, 2020. Recent Highlights Total revenue of $10.6 million including four platform placements Completed initial public offering, raising approximately $188 million of net proceeds Second Quarter 2020 Financial Results Revenue was $10.6 million for the quarter ended June 30, 2020, representing a 10% d
-
Berkeley Lights Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - July 21, 2020
7/21/2020
Berkeley Lights, Inc. announced the closing of its initial public offering of 9,315,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,215,000 shares of common stock, at a public offering price of $22.00 per share.
-
Berkeley Lights Announces Pricing of Initial Public Offering
7/16/2020
Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the pricing of its initial public offering of 8,100,000 shares of common stock at a public offering price of $22.00 per share.
-
Berkeley Lights Announces Opto™ Antigen-Presenting Bead Kit to Accelerate the Expansion of Antigen-Specific T Cells Used to Develop Cell-Based Therapies
6/24/2020
Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the Opto Antigen-Presenting Bead (APB) kit, a new reagent kit that activates and expands antigen-specific T cells in peripheral blood to create artificial T cells.
-
Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies
4/27/2020
The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights' platform develop cancer immunotherapies faster
-
Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies
4/22/2020
Ablexis, LLC , AlivaMab Discovery Services, LLC ("ADS") and Berkeley Lights, Inc. today announced the rapid generation and recovery of sequences encoding a rich panel of human antibodies against the S1 spike protein of the S
-
Berkeley Lights Expands Its Platform and Introduces the OptoSeq™ 3' mRNA Library Kit
3/31/2020
The OptoSeq 3' mRNA Library Kit allows users of Berkeley Lights' platform to efficiently prepare cells of interest for genomic sequencing opening the door to directly link phenotype to genotype using a single system.
-
Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics
3/9/2020
The Opto™ Cell Line Development 2.0 workflow, designed for the Beacon® optofluidic instrument, generates in just days the best production cell lines for complex antibody therapeutics with more than 99% monoclonality assurance [09-March-2020] EMERYVILLE, Calif. , March 9, 2020 /PRNewswire/ -- Today, Berkeley Lights, a leader in cell selection, launched a new workflow f
-
Berkeley Lights Launches Culture Station to Increase Capacity of its Beacon® and Lightning™ Optofluidic Platforms
1/28/2020
The Culture Station increases the throughput of screened cells on the Berkeley Lights optofluidic platforms and optimizes experimental conditions, allowing users to run more independent experiments in parallel.
-
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
-
Berkeley Lights Awarded One of The Scientist's Top Ten Innovations of 2019 for the Lightning™ Optofluidic Platform
12/2/2019
The Scientist's award identifies exciting laboratory technologies that have the potential to foster rapid advances or generate the biggest impact on research.
-
Ginkgo Bioworks and Berkeley Lights Bring Unprecedented Speed and Scale to Synthetic Biology with $150MM Collaboration
10/1/2019
Collaboration brings best-in-class technology to Ginkgo foundries, with a commitment to ongoing joint technology development
-
Berkeley Lights Opens Shanghai Location
9/5/2019
Berkeley Lights, Inc. announced the opening of a representative office in Pudong, Shanghai.
-
BioSpace Movers and Shakers, Aug. 9
8/9/2019
Biopharma companies strengthen their senior leadership teams and boards of directors. -
Berkeley Lights to Launch New T Cell Functional Analytics Platform at the 34ᵗʰ Congress of the International Society for Advancement of Cytometry (CYTO)
6/18/2019
Berkeley Lights, Inc. announced the launch of the LightningTM optofluidic platform, which directly visualizes phenotype and function of 1000s of T cells in days to help scientists address challenges in developing cancer immunotherapies.
-
Abveris Deploys the Berkeley Lights Beacon® Platform for Antibody Discovery
6/17/2019
Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services.
-
Berkeley Lights Selected as One of the World's Most Innovative Companies of 2019 by Fast Company
2/20/2019
Berkeley Lights, Inc., a leader in digital cell biology, announced that it has been named one of Fast Company's 2019 Most Innovative Companies in Biotech.
-
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
-
Movers and Shakers for Sept. 4
9/4/2018
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look. -
Shire Adopts Berkeley Lights' Beacon OptoFluidic Platform to Speed Cell Line Development
1/30/2018
Shire's decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon.